Impact of Migraine on Work Productivity in Patients Treated With a Combination Product Containing Sumatriptan and Naproxen Sodium or Triptan Monotherapy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01381497
First received: June 23, 2011
Last updated: August 23, 2012
Last verified: August 2012
  Purpose

Migraine headaches lead to absenteeism and can restrict on-the-job productivity (presenteeism) for employed migraine sufferers. Effective migraine treatments should reduce migraine-associated productivity losses and return migraineurs to normal functioning within a few hours of treatment.

This study is an observational, multicenter, parallel-group study of employed patients who have been prescribed either a combination product containing sumatriptan and naproxen sodium (SumaRT/Nap) or oral triptan monotherapy to treat acute migraine attacks. The study will report results from 4 migraine attacks per patient. Eligible migraine attacks will be defined as those preceded by a 24-hour, headache-free period with onset between 2 hours prior to the start of and 4 hours before the end of a scheduled work shift. Data will be collected at time of treatment and hourly until the end of the attack or the end of the workday. To estimate baseline productivity, data will be collected from 50 randomly selected subjects during a migraine-free workday.

The primary objective of this study is to compare migraine-related, work productivity losses (absenteeism and presenteeism) reported by patients treated with SumaRT/Nap to losses reported by patients treated with triptan monotherapy. The null hypothesis is that no difference will be observed between the number of hours of productivity lost for patients who treat workday migraine attacks with SumaRT/Nap and patients who treat migraine attacks with an oral triptan alone. The alternative hypotheses are that patients in either treatment group experience significantly fewer hours of lost productivity associated with migraine compared to patients in the other treatment group.

The secondary objectives of this study are to measure the time between treatment and return to patient-reported, normal functioning; to evaluate rescue medication use after initial treatment; to measure total productivity loss following treatment at hourly time points; and to estimate the probability of absenteeism when a migraine begins before or during the workday. The null hypotheses for the secondary endpoints are that no differences will be observed between the results reported by patients treating with SumaRT/Nap and patients treating with triptan monotherapy. The alternative hypotheses are that either treatment is superior to the other for each endpoint.


Condition Intervention
Migraine Disorders
Drug: Combination therapy of sumatriptan and naproxen sodium (SumaRT/Nap)
Drug: Triptan monotherapy

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Impact of Migraine on Work Productivity in Patients Treated With a Combination Product Containing Sumatriptan and Naproxen Sodium or Triptan Monotherapy

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Total Lost Productivity (absenteeism and presenteeism) measured by Lost Time Equivalents [ Time Frame: Four qualifying migraine attacks must occur within 16 weeks of enrollment. Data collection begins at time of treatment and continues in hourly intervals until the end of the migraine attack or the end of the workday. ] [ Designated as safety issue: No ]
    Lost Time Equivalents = hours missed from work + [(100% - % effectiveness while working with symptoms)/100 x hours working with symptoms].


Secondary Outcome Measures:
  • Percentage of patients returning to normal functioning as measured by the Clinical Disability Questionnaire (CDQ) [ Time Frame: At time of treatment for a qualifying attack and at hourly intervals post treatment until end of migraine attack or end of workday ] [ Designated as safety issue: No ]
    The CDQ uses one question to assess ability to perform normal or usual activities. Responses are recorded on a 5-point scale, where 1 is "normal/not impaired", 2 is "mildly impaired", 3 is "moderately impaired", 4 is "severely impaired", and 5 is '"required bedrest". Normal functioning is considered a score of "1"

  • Rescue medication [ Time Frame: Rescue medication is prohibited within 2 hours of study treatment administration. Rescue medication use is measured between 2 and 4 hours post treatment ] [ Designated as safety issue: No ]
    For patients who need pain relief in addition to the study treatment, rescue medication is allowed and measured. Type of rescue medication will be allowed at the discretion of the investigator and within the guidelines of the package insert for the study medication

  • Number of missed work hours and presenteeism hours lost following treatment measured in hours [ Time Frame: At time of treatment for a qualifying attack and hourly intervals post treatment until end of migraine attack or end of workday ] [ Designated as safety issue: No ]
    Measured as per the primary endpoint and reported hourly

  • Probability of absenteeism during a morning migraine attack [ Time Frame: At time of treatment for a qualifying attack and hourly intervals post treatment until end of migraine attack or end of workday ] [ Designated as safety issue: No ]
    A subgroup analysis will be conducted to provide information about the probability that patients will be absent if the migraine onset occurs in the morning


Enrollment: 1
Study Start Date: March 2010
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Employed migraine sufferers
Diagnosed adult migraine sufferers who are employed at least 30 hours per week during a daytime shift
Drug: Combination therapy of sumatriptan and naproxen sodium (SumaRT/Nap)
This is an observational study and patients were prescribed this medication before study start
Other Name: Treximet®
Drug: Triptan monotherapy
This is an observational study and patients reported a previous triptan monotherapy prescription. Drugs of interested included naratriptan, sumatriptan, rizatriptan, frovatriptan, almotriptan, eletriptan, zolmitriptan
Other Names:
  • Zomig® is a registered trademark of AstraZeneca
  • Amerge® is a registered trademark of GlaxoSmithKline
  • Axert® is a registered trademark of Pharmacia
  • Frova® is a registered trademark of Elan Pharmaceuticals/UCB Pharma
  • Inc
  • Maxalt® is a registered trademark of Merck & Co
  • Imitrex® is a registered trademark of GlaxoSmithKline
  • Relpax® is a registered trademark of Pfizer

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Adult males and females aged 18 to 65 with a diagnosis of migraine disorder who are employed and scheduled to work at least 30 hours per week during a day time shift. Patients must be treating migraines with either a combination therapy of sumatriptan and naproxen sodium (SumaRT/Nap) or oral triptan monotherapy as prescribed prior to study start. Patients will be recruited from up to 30 investigative sites.

Criteria

Inclusion Criteria:

  • Age 18 to 65
  • Currently treating migraine attacks with SumaRT/Nap or oral triptan monotherapy
  • Have a diagnosis of migraine with or without aura (2004 International Classification of Headache Disorders (ICHD)-II criteria)
  • Have had at least 2 but not more than 8 migraine attacks per month in the previous 2 months
  • Score 56 or higher on the Headache Impact Test 6 (HIT-6)
  • Be actively employeed for at least 30 hours per week and working a day time shift (beginning between 6 and 11 AM)
  • Have experienced and treated a disabling migraine in the work place during the month prior to screening
  • Be willing to treat a mild, moderate, or severe migraine in the work place with usual medication (SumaRT/Nap or oral triptan alone)
  • Be willing to adhere to protocol requirements including, but not limited to, hourly phone calls from the Interactive Voice-Activated Recording System (IVRS) and clinic visits
  • Have an active cell phone with a plan that has sufficient monthly minutes during the study period to collect data via IVRS and be willing to provide their cell phone number to the study team
  • Consent to phone the IVRS at the onset of a migraine attack during or prior to the workday and receive up to 8 phone calls (1 to 2 minutes each) during the workday.
  • Be able to distinguish migraine attacks from other headache types
  • Be able to hear, understand, and verbally answer questions from the IVRS in English
  • Be willing and able to give written informed consent to participate in the study
  • Female subjects of childbearing potential must use a reliable method of birth control as agreed upon by their investigator or male partner who is physiologically or surgically sterile. Any subject taking oral contraceptives must be on a stable regimen for at least two months prior to screening.

Exclusion Criteria:

  • Subject often treats migraine attacks with a combination of a single entity triptan and any other medication
  • Has 15 or more headache days per month in total, retinal (ICH-II 1.4), basilar (ICHD-II 1.26) or hemiplegic migraine (ICHD-II 1.25), or secondary headaches
  • Has a HIT-6 score below 56 at screening
  • Works an evening or night shift or works from home
  • Has hypersensitivity, allergy, intolerance, or contraindication to any triptan or non-steriodal anti-inflammatory (NSAID) drug including aspirin and all sumatriptan and naproxen preparations.
  • Has nasal polyps or asthma
  • Is currently taking, or has taken in the 2 weeks prior to screening, a migraine prophylactic medication containing methylsergide or dihydroergotamine; or is takign a medication that is not stablized (i.e. change of dose within the previous two months) for intermittant migraine prophylaxis or for a co-morbid condition that is not stablized
  • Has a recent history of regular use of opioids or barbituates for treatment of their migraine headache and/or other non-migraine pain. Regular use is defined as an average of 4 days per month during any month over the last 3 months
  • Has taken or plans to take a monoamine oxidase (MAOI) inhibitor including herbal preparations containing St. John's Wort (Hypericum perforatum) anytime within the 2 weeks prior to screening through 2 weeks post final study treatment
  • Is pregnant, actively trying to become pregnant, or breast feeding
  • Has evidence of alcohol or substance abuse within the last year or any concurrent medical or psychiatric condition which, in the investigator's judgement, will likely interfere with the study conduct, subject cooperation, or evaluation and interpretation of the study results, or which otherwise contraindicates participation in this clinical trial
  • Has participated in an investigational drug trial within the previous 4 weeks or plans to participate in another study at any time during this study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01381497

Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01381497     History of Changes
Other Study ID Numbers: 112617
Study First Received: June 23, 2011
Last Updated: August 23, 2012
Health Authority: United States: No Health Authority

Keywords provided by GlaxoSmithKline:
presenteeism
migraine disorders
work productivity
triptan
sumatriptan and naproxen sodium
absenteeism

Additional relevant MeSH terms:
Migraine Disorders
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Naproxen
Sumatriptan
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Inflammatory Agents
Therapeutic Uses
Antirheumatic Agents
Gout Suppressants
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Central Nervous System Agents
Vasoconstrictor Agents
Cardiovascular Agents
Serotonin 5-HT1 Receptor Agonists
Serotonin Receptor Agonists
Serotonin Agents
Neurotransmitter Agents

ClinicalTrials.gov processed this record on September 18, 2014